InMode offers a cash-rich, deeply discounted bet on minimally invasive aesthetic technology, but investors must believe its margin pressure and North American slowdown are temporary—not the start of commoditization.
Overview
InMode is a global medical aesthetics leader built around proprietary energy-based platforms that deliver surgical-like results with less downtime, scarring, and anesthesia risk. Its revenue model blends high-value capital equipment with recurring consumables and services, supported by an installed base above 30,000 systems. The U.S. remains the largest market, while international sales now approach half of revenue. Flagship technologies such as Morpheus8, BodyTite, FaceTite, and EvolveX position the company strongly in minimally invasive RF aesthetics, with newer wellness, ophthalmology, and women’s health platforms broadening its addressable market.